BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21480360)

  • 1. "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
    Schulze Zur Wiesch J; Pudelski N; Hoepner L; Supplieth M; Buggisch P; Lohse AW; Lüth S
    Hepatology; 2011 Apr; 53(4):1405-6; author reply 1407. PubMed ID: 21480360
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
    Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
    Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
    Liu CH; Liang CC; Liu CJ; Tsai HB; Hung PH; Hsu SJ; Chen SI; Lin JW; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
    Gut; 2009 Feb; 58(2):314-6. PubMed ID: 19136527
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
    Nayman Alpat S; Usluer G; Yavuz H; Doyuk Kartal E; Erben N; Bal C; Ozgunes I
    J Chemother; 2008 Feb; 20(1):101-5. PubMed ID: 18343751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
    Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F
    Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
    Chou R; Carson S; Chan BK
    J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
    J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating hepatitis C: are children the same as adults?
    Delgado-Borrego A
    Gastroenterology; 2011 Feb; 140(2):389-92. PubMed ID: 21172331
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.
    Fung J; Lai CL; Hung I; Young J; Cheng C; Wong D; Yuen MF
    J Infect Dis; 2008 Sep; 198(6):808-12. PubMed ID: 18657036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Peginterferon alpha-2a and ribavirin for treating chronic hepatitis C patients with persistent normal aminotransferase levels].
    Jiang TJ; Fan R; Xie YX; Zhao P; Zhang X; Zhao M; Zhou ZP; He J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Apr; 16(4):307-8. PubMed ID: 18423159
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.